Gelecekte Nonavalent (9-valent) HPV Aşısının Türkiye İçin Kullanılabilirliği
HPV enfeksiyonu servikal kanser gelişimi için en önemli neden olup,serviks kanseri vakalarının yaklaşık %70’i HPV tip 16 ve 18’e bağlıolarak gelişir. İkili ve dörtlü HPV aşıları yüksek riskli HPV grubundan tip16 ve 18’e karşı etkili iken, Nonavalent HPV aşısı ek olarak yüksek riskliHPV tip 31, 33, 45, 52, ve 58’e karşı da etkinlik gösterir. Türkiye’deendemik görülen HPV tipleri; 16, 51, 31, 52, 56, 39, 58 45, 33 ve 18dikkate alındığında ülkemiz için Nonavalent HPV aşısına ihtiyaç daha netolarak anlaşılacaktır.
Future Feasibility Of Nonavalent (9-valent) HPV Vaccine in Turkey
HPV infection is the most important reason for the development of cervical cancer and HPV type 16 and 18 are responsible for 70% of cervical cancer cases. Bivalent and quadrivalent HPV vaccines are effective against HPV type 16 and 18 among the high risk HPV group, however Nonavalent HPV vaccine provides additional effectiveness against HPV type 31, 33, 45, 52 and 58 among the high risk HPV group. Endemic HPV types detected in Turkey; 16, 51, 31, 52, 56, 39, 58 45, 33 and 18, clearly indicate the need for Nonavalent HPV vaccine for Turkey.
___
- Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006;110(5):525-41.
- Schiffman M, Wentzensen N. Human papillomavirus infection and the
multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(4):553-60.
- Chan PK, Chang AR, Yu MY, Li WH, Chan MY, Yeung AC, et al. Age distribution of human papillomavirus infection and cervical neoplasia reflects
caveats of cervical screening policies. Int J Cancer. 2010;126(1):297-
301.
- Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV,
et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-27.
- Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev.
2003;16(1):1-17.
- Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J,
Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30 Suppl 5:F12-23.
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al.
Cancer incidence and mortality worldwide: sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
- Gultekin M, Kucukyildiz I, Karaca MZ, Dundar S, Boztas G, Turan SH, et al.
Trends of Gynecological Cancers in Turkey: Toward Europe or Asia? Int J
Gynecol Cancer. 2017;27(8S Suppl 1):S1-S9.
- Gultekin M, Dundar S, Kucukyildiz I, Karaca MZ, Boztas G, Turan SH, et al.
Survival of gynecological cancers in Turkey: where are we at? J Gynecol
Oncol. 2017;28(6):e85.
- Beutner KR, Tyring S. Human papillomavirus and human disease. Am J
Med. 1997;102(5A):9-15.
- McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW,
et al. Natural history of cervical neoplasia and risk of invasive cancer in
women with cervical intraepithelial neoplasia 3: a retrospective cohort
study. Lancet Oncol. 2008;9(5):425-34.
- Vink MA, Bogaards JA, van Kemenade FJ, de Melker HE, Meijer CJ,
Berkhof J. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly
censored national registry data. Am J Epidemiol. 2013;178(7):1161-9.
- Safaeian M, Solomon D, Castle PE. Cervical cancer prevention--cervical screening: science in evolution. Obstet Gynecol Clin North Am.
2007;34(4):739-60, ix.
- Gultekin M, Zayifoglu Karaca M, Kucukyildiz I, Dundar S, Boztas G, Semra
Turan H, et al. Initial results of population based cervical cancer screening
program using HPV testing in one million Turkish women. Int J Cancer.
2018;142(9):1952-8.
- Mayrand MH, Duarte-Franco E, Coutlee F, Rodrigues I, Walter SD, Ratnam
S, et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors:
design, methods and preliminary accrual results of the Canadian cervical
cancer screening trial (CCCaST). Int J Cancer. 2006;119(3):615-23.
- Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al.
Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet.
2014;383(9916):524-32.
- Stanley M. HPV - immune response to infection and vaccination. Infect
Agent Cancer. 2010;5:19.
- Stanley M. Prophylactic HPV vaccines. J Clin Pathol. 2007;60(9):961-5.
- Harper DM, DeMars LR. HPV vaccines - A review of the first decade.
Gynecol Oncol. 2017;146(1):196-204.
- Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et
al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of
infection with human papillomavirus types 16 and 18 in young women: a
randomised controlled trial. Lancet. 2004;364(9447):1757-65.
- Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al.
Immunologic responses following administration of a vaccine targeting
human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006;24(27-
28):5571-83.
- Mariani L, Preti M, Cristoforoni P, Stigliano CM, Perino A. Overview of the
benefits and potential issues of the nonavalent HPV vaccine. Int J Gynaecol Obstet. 2017;136(3):258-65.
- Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Jr., Aranda C, Jessen
H, et al. HPV vaccine against anal HPV infection and anal intraepithelial
neoplasia. N Engl J Med. 2011;365(17):1576-85.
- Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV;
types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and
disease due to oncogenic nonvaccine HPV types in generally HPV-naive
women aged 16-26 years. J Infect Dis. 2009;199(7):926-35.
- Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J,
Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted
vaccine against cervical infection and precancer caused by non-vaccine
oncogenic HPV types: 4-year end-of-study analysis of the randomised,
double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):100-10.
- Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, et al.
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised,
double-blind trial. Lancet. 2017;390(10108):2143-59.
- Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al.
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in
women. N Engl J Med. 2015;372(8):711-23.
- Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy
against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009;5(10):696-
704.
- Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al.
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine
against cervical infection and precancer caused by oncogenic HPV types
(PATRICIA): final analysis of a double-blind, randomised study in young
women. Lancet. 2009;374(9686):301-14.
- World Health Organization. Electronic address swi. Human papillomavirus
vaccines: WHO position paper, May 2017-Recommendations. Vaccine.
2017;35(43):5753-5.
- Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K. Safety
of Human Papillomavirus Vaccines: An Updated Review. Drug Saf.
2018;41(4):329-46.
- Moreira ED, Jr., Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, et
al. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7
Phase III Clinical Trials. Pediatrics. 2016;138(2).
- Kosalaraksa P, Mehlsen J, Vesikari T, Forsten A, Helm K, Van Damme P,
et al. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and
poliomyelitis vaccines to healthy adolescents 11-15 years of age. Pediatr
Infect Dis J. 2015;34(6):627-34.
- Schilling A, Parra MM, Gutierrez M, Restrepo J, Ucros S, Herrera T, et
al. Coadministration of a 9-Valent Human Papillomavirus Vaccine With
Meningococcal and Tdap Vaccines. Pediatrics. 2015;136(3):e563-72.